232 related articles for article (PubMed ID: 1349939)
1. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.
Falini B; Bolognesi A; Flenghi L; Tazzari PL; Broe MK; Stein H; Dürkop H; Aversa F; Corneli P; Pizzolo G
Lancet; 1992 May; 339(8803):1195-6. PubMed ID: 1349939
[TBL] [Abstract][Full Text] [Related]
2. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
Tazzari PL; Bolognesi A; de Totero D; Falini B; Lemoli RM; Soria MR; Pileri S; Gobbi M; Stein H; Flenghi L
Br J Haematol; 1992 Jun; 81(2):203-11. PubMed ID: 1322690
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B
Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.
Pasqualucci L; Wasik M; Teicher BA; Flenghi L; Bolognesi A; Stirpe F; Polito L; Falini B; Kadin ME
Blood; 1995 Apr; 85(8):2139-46. PubMed ID: 7718885
[TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro uptake of an anti-CD30/saporin immunotoxin by rat liver parenchymal and nonparenchymal cells.
Battelli MG; Buonamici L; Bolognesi A; Stirpe F
Hepatology; 1994 Oct; 20(4 Pt 1):940-7. PubMed ID: 7927236
[TBL] [Abstract][Full Text] [Related]
6. Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.
Sforzini S; de Totero D; Gaggero A; Ippoliti R; Glennie MJ; Canevari S; Stein H; Ferrini S
Br J Haematol; 1998 Sep; 102(4):1061-8. PubMed ID: 9734659
[TBL] [Abstract][Full Text] [Related]
7. Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies.
Sforzini S; Bolognesi A; Meazza R; Marciano S; Tazzari PL; Stein H; Stirpe F; Ferrini S
J Hematother; 1995 Oct; 4(5):429-32. PubMed ID: 8581380
[TBL] [Abstract][Full Text] [Related]
8. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence.
Falini B; Flenghi L; Fedeli L; Broe MK; Bonino C; Stein H; Dürkop H; Bigerna B; Barbabietola G; Venturi S
Br J Haematol; 1992 Sep; 82(1):38-45. PubMed ID: 1329918
[TBL] [Abstract][Full Text] [Related]
9. Experimental therapy in Hodgkin's disease.
Engert A; Pohl C; Diehl V
Ann Oncol; 1992 Sep; 3 Suppl 4():97-100. PubMed ID: 1333274
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
[TBL] [Abstract][Full Text] [Related]
11. In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins.
Bolognesi A; Polito L; Tazzari PL; Lemoli RM; Lubelli C; Fogli M; Boon L; de Boer M; Stirpe F
Br J Haematol; 2000 Aug; 110(2):351-61. PubMed ID: 10971392
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD30 immunotoxins with native and recombinant dianthin 30.
Bolognesi A; Tazzari PL; Legname G; Olivieri F; Modena D; Conte R; Stirpe F
Cancer Immunol Immunother; 1995 Feb; 40(2):109-14. PubMed ID: 7882380
[TBL] [Abstract][Full Text] [Related]
14. Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation.
Tazzari PL; Bolognesi A; De Totero D; Lemoli RM; Fortuna A; Conte R; Crumpton MJ; Stirpe F
Br J Haematol; 1994 Jan; 86(1):97-105. PubMed ID: 7912101
[TBL] [Abstract][Full Text] [Related]
15. Hodgkin's disease. Future treatment strategies: fact or fiction?
Schnell R; Barth S; Diehl V; Engert A
Baillieres Clin Haematol; 1996 Sep; 9(3):573-93. PubMed ID: 8922247
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins.
Bolognesi A; Tazzari PL; Olivieri F; Polito L; Falini B; Stirpe F
Int J Cancer; 1996 Nov; 68(3):349-55. PubMed ID: 8903477
[TBL] [Abstract][Full Text] [Related]
17. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin.
Urch CE; George AJ; Stevenson GT; Bolognesi A; Stirpe F; Weller R; Glennie MJ
Int J Cancer; 1991 Apr; 47(6):909-15. PubMed ID: 2010234
[TBL] [Abstract][Full Text] [Related]
18. Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies.
Ferrini S; Sforzini S; Canevari S
Methods Mol Biol; 2001; 166():177-92. PubMed ID: 11217367
[No Abstract] [Full Text] [Related]
19. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
Schnell R; Staak O; Borchmann P; Schwartz C; Matthey B; Hansen H; Schindler J; Ghetie V; Vitetta ES; Diehl V; Engert A
Clin Cancer Res; 2002 Jun; 8(6):1779-86. PubMed ID: 12060617
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
